[Benefit assessment in special situations--rare diseases]

Area of Science:

• Clinical trial methodology
• Rare disease research
• Evidence-based medicine

Context:

• Rare disease definitions lack uniformity, with some large enough for clinical trials.
• Smaller patient populations in rare disease trials increase the risk of imprecise results.
• Methodological compromises in rare disease studies are sometimes used to justify inadequate designs.

Purpose:

• To challenge the notion that rare diseases preclude robust clinical trial designs.
• To advocate for adequate methodological standards in rare disease research.
• To emphasize the right of rare disease patients to well-tested treatments.

Summary:

• The term "rare disease" is frequently misused to avoid implementing rigorous study designs like randomization.
• Despite varying definitions, many rare diseases have sufficient patient numbers for effective clinical trials.
• Inadequate designs amplify the risk of imprecise results for rare disease patients, which is unjustifiable.

Impact:

• Promoting higher methodological standards in rare disease clinical trials.
• Ensuring rare disease patients receive treatments supported by adequate evidence.
• Advancing equitable research practices across all disease categories.